

A SISTER'S HOPE



Cancer Institute

Brief summary of progress for A Sister's Hope, January 2014

Sensitivity to cisplatin chemotherapy determined in circulating tumor cells

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

The aim of this study is to prospectively explore the predictive value of a cisplatin (cDDP) chemotherapy sensitivity profile determined in circulating tumor cells (CTCs) of heavily pretreated metastatic breast cancer patients. To investigate this, CTCs are enumerated and characterized in consenting patients with metastatic breast cancer, who have been pretreated with at least anthracycline- and taxane-based chemotherapy in the adjuvant and/or metastatic setting, receiving 3-weekly cDDP at 70 mg/m² for a maximum of 6 cycles.

Thanks to funds that were made available by A Sister's Hope, accrual for this study was able to start in June 2013 in the Erasmus MC Cancer Institute, while two community hospitals in Rotterdam (Sint Franciscus Gasthuis and Ikazia Ziekenhuis) started accrual in August 2013. We expect that a fourth hospital in Antwerp, Belgium (Sint-Augustinus) will start accrual in March 2014. At the moment of submitting this brief summary, a significant number of patients have already been treated with cisplatin according to protocol. Accrual in this study will continue until 10 evaluable patient harboring a favorable CTC cDDP sensitivity profile have been included.

At this point, no preliminary results are available yet, since the evaluations of the CTC cDDP sensitivity profile as determined in CTCs will be performed in batch analyses. We expect the first evaluation to take place in March 2014. Following this first evaluation, we will know how many patients harboring a favorable CTC cDDP sensitivity profile have been included. In the following months, accrual in this study will continue to take place.

Prof. Stefan Sleijfer, MD, PhD, medical oncologist, principal investigator
Nick Beije, MD, PhD student, study coordinator